Syndax Pharmaceuticals Inc Cash Flow Conversion Efficiency
Syndax Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Syndax Pharmaceuticals Inc (SNDX) has a cash flow conversion efficiency ratio of -2.005x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.27 Million) by net assets ($15.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Syndax Pharmaceuticals Inc (2011–2025)
Cash flow conversion efficiency of Syndax Pharmaceuticals Inc from 2011 to 2025. This chart illustrates how Syndax Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Syndax Pharmaceuticals Inc stock quote for real-time trading data and today's change.
Syndax Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Syndax Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Syndax Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Syndax Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Syndax Pharmaceuticals Inc (SNDX) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
North China Pharmaceutical Co Ltd
SHG:600812
|
0.025x |
|
Smartgroup Corporation Ltd
AU:SIQ
|
0.253x |
|
Avanos Medical Inc
NYSE:AVNS
|
-0.016x |
|
Grupo Televisa S.A.B.
F:TLV
|
0.100x |
|
Beijing Urban Construction Investment & Development Co Ltd
SHG:600266
|
0.032x |
|
U-Haul Holding Company
NYSE:UHAL
|
0.031x |
|
First Mid Illinois Bancshares Inc
NASDAQ:FMBH
|
0.039x |
|
Implenia AG
SW:IMPN
|
-0.141x |
Annual Cash Flow Conversion Efficiency for Syndax Pharmaceuticals Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Syndax Pharmaceuticals Inc from 2011 to 2025. Review Syndax Pharmaceuticals Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $64.63 Million | $-322.98 Million | -4.997x | -423.77% |
| 2024-12-31 | $288.12 Million | $-274.90 Million | -0.954x | -229.24% |
| 2023-12-31 | $554.20 Million | $-160.60 Million | -0.290x | -1.34% |
| 2022-12-31 | $467.45 Million | $-133.68 Million | -0.286x | -500.88% |
| 2021-12-31 | $408.37 Million | $29.13 Million | 0.071x | +125.25% |
| 2020-12-31 | $252.19 Million | $-71.26 Million | -0.283x | +82.36% |
| 2019-12-31 | $31.60 Million | $-50.61 Million | -1.602x | -23.98% |
| 2018-12-31 | $53.05 Million | $-68.53 Million | -1.292x | -184.50% |
| 2017-12-31 | $104.32 Million | $-47.37 Million | -0.454x | -8.68% |
| 2016-12-31 | $84.14 Million | $-35.16 Million | -0.418x | -1047.83% |
| 2015-12-31 | $66.70 Million | $-2.43 Million | -0.036x | -101.45% |
| 2014-12-31 | $-5.72 Million | $-14.39 Million | 2.518x | +508.99% |
| 2013-12-31 | $11.85 Million | $-7.29 Million | -0.616x | -294.22% |
| 2012-12-31 | $-29.29 Million | $-9.28 Million | 0.317x | -39.73% |
| 2011-12-31 | $-19.05 Million | $-10.02 Million | 0.526x | -- |
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. Th… Read more